Cargando…

Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy

INTRODUCTION/AIMS: There is limited information on the potential effects of repeated intrathecal antisense oligonucleotide drug delivery on cerebrospinal fluid (CSF) biochemical and blood cell profiles. This study aimed to examine longitudinal changes in the biochemical components (glucose, protein)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orbach, Rotem, Sagi, Liora, Sadot, Efraim, Tokatly Latzer, Itay, Shtamler, Anna, Zisberg, Tehila, Fattal‐Valevski, Aviva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Clinical Research Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828332/ https://www.ncbi.nlm.nih.gov/pubmed/36214191 http://dx.doi.org/10.1002/mus.27731

Ejemplares similares

Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients
por: Magen, Iddo, et al.
Publicado: (2022)

Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy
por: Kotulska, Katarzyna, et al.
Publicado: (2021)

Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience
por: Haché, Manon, et al.
Publicado: (2016)

Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
por: Stolte, Benjamin, et al.
Publicado: (2018)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy
por: Cordts, Isabell, et al.
Publicado: (2020)

Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy
por: Beaudin, Marie, et al.
Publicado: (2023)

Intrathecal administration of nusinersen for spinal muscular atrophy: report of three cases with severe spinal deformity
por: Nakao, Sayo, et al.
Publicado: (2020)

Radiation dose reduction for CT-guided intrathecal nusinersen administration in adult patients with spinal muscular atrophy
por: Cordts, Isabell, et al.
Publicado: (2020)

Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021)

Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen
por: Wurster, Claudia D., et al.
Publicado: (2019)

Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients
por: Bianchi, Laura, et al.
Publicado: (2021)

Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy
por: Li, Qing
Publicado: (2020)

Nusinersen and Spinal Muscular Atrophies: Where are we in 2020?
por: Khadilkar, Satish V., et al.
Publicado: (2020)

Clinical Implication of Dosimetry of Computed Tomography- and Fluoroscopy-Guided Intrathecal Therapy With Nusinersen in Adult Patients With Spinal Muscular Atrophy
por: Kizina, Kathrin, et al.
Publicado: (2019)

Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients
por: Faravelli, Irene, et al.
Publicado: (2020)

Ultra-low radiation dose protocol for CT-guided intrathecal nusinersen injections for patients with spinal muscular atrophy and severe scoliosis
por: Rosiak, Grzegorz, et al.
Publicado: (2021)

Fatigue in adults with spinal muscular atrophy under treatment with nusinersen
por: Kizina, K., et al.
Publicado: (2020)

Parents’ perspectives on nusinersen treatment for children with spinal muscular atrophy
por: van Kruijsbergen, Mette, et al.
Publicado: (2021)

Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study
por: Acsadi, Gyula, et al.
Publicado: (2021)

Nusinersen: A Review in 5q Spinal Muscular Atrophy
por: Hoy, Sheridan M.
Publicado: (2021)

Scoliosis in Spinal Muscular Atrophy Type 1 in the Nusinersen Era
por: Al Amrani, Fatima, et al.
Publicado: (2022)

Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
por: Nuzzo, Tommaso, et al.
Publicado: (2023)

Scoliosis Orthopedic Surgery Combined With Nusinersen Intrathecal Injection Significantly Improved the Outcome of Spinal Muscular Atrophy Patient: A Case Report
por: Xu, Beiyu, et al.
Publicado: (2022)

Is cerebrospinal fluid amyloid‐β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?
por: Introna, Alessandro, et al.
Publicado: (2021)

Nusinersen in type 0 spinal muscular atrophy: should we treat?
por: Tiberi, Eloisa, et al.
Publicado: (2020)

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
por: Pera, Maria Carmela, et al.
Publicado: (2021)

Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy
por: Hoy, Sheridan M.
Publicado: (2021)

History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy
por: Qiu, Jiaying, et al.
Publicado: (2022)

Sleep Quality and Eating Disorder-Related Psychopathologies in Patients with Night Eating Syndrome and Binge Eating Disorders
por: Tzischinsky, Orna, et al.
Publicado: (2021)

Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy
por: Strauss, Kevin A., et al.
Publicado: (2018)

Intrathecal Administration of Nusinersen Using the Ommaya Reservoir in an Adult with 5q-Related Spinal Muscular Atrophy Type 1 and Severe Spinal Deformity
por: Papaliagkas, Vasileios, et al.
Publicado: (2021)

Unilateral interlaminar fenestration on the convex side provides a reliable access for intrathecal administration of nusinersen in spinal muscular atrophy: a retrospective study
por: Wang, Zhen, et al.
Publicado: (2023)

Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen
por: Totzeck, Andreas, et al.
Publicado: (2019)

Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
por: Thokala, Praveen, et al.
Publicado: (2020)

Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients
por: Osmanovic, Alma, et al.
Publicado: (2021)

Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
por: Osmanovic, Alma, et al.
Publicado: (2021)

Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
por: Freigang, Maren, et al.
Publicado: (2021)

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
por: Elsheikh, Bakri, et al.
Publicado: (2021)

Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen
por: Kariyawasam, Didu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iiriishb1jphq1j0j7i5bduo4c